Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Podpisana zgoda na udział w badaniu
- •Zaawansowany rak piersi, który nie można operować, z potwierdzonym rozpoznaniem
- •Rak piersi dodatni na receptory hormonalne (estrogen i/lub progesteron)
- •Wcześniejsze leczenie inhibitorem CDK4/6 (jako monoterapia lub z hormonoterapią)
- •1-4 poprzednie chemioterapie w zaawansowanym stadium choroby
- •Wcześniejsze leczenie lekiem T-DXd
- •Stan ogólny pacjenta oceniony na 0-2 wg skali ECOG
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- December 26, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, United States
Miami Cancer Institute at Baptist Health, Inc.
Miami, United States
Winship Cancer Institute at Emory University
Atlanta, United States
Trial contact
Reshma L Mahtani, D.O.
Krystal Fernandez
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.